Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment

Rose Ann Padua, PhD, Laure Sarda-Mantel, MD PhD, Mathieu Chiquet, BSc, Claire Kappel, BSc, Patricia Krief, PhD, Niclas Setterblad, PhD, Fortune Hontonnou, BSc, Benoit Hosten, PhD, Nicolas Vignal, BSc, Fabien Zassadowski, PhD, Bruno Cassinat, PharmD, PhD, Panhong Gou, BSc, Stephane Giraudier, MD PhD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Marika PLA, PhD, Lionel Ades, MD PhD, Pierre Fenaux, MD PhD, Christine Chomienne, MD PhD

Blood (2018) 132 (Supplement 1): 5497.

https://doi.org/10.1182/blood-2018-99-114212

Published: 2018

Journal Articles

BCL-2 Inhibition with ABT-199 Shows Efficacy in AML Cell Lines with Synergistic Effects upon Addition of the MEK Inhibitor GDC-0973 and Prolongs Survival in an NAS/BCL-2-Mediated Mouse Model of AML Post-MDS

Rose Ann Padua, PhD, Mathieu Chiquet, BSc, Qi Zhang, PhD MD, Claire Kappel, Patricia Krief, PhD, Niclas Setterblad, PhD, Dr Omidvar, BSc, MSc, PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Marika PLA, PhD, Lionel Ades, MD PhD, Pierre Fenaux, MD PhD, Christine Chomienne, MD PhD

Blood (2017) 130 (Supplement 1): 2613.

https://doi.org/10.1182/blood.V130.Suppl_1.2613.2613

Published: 2017

Journal Articles

Efficacy of ABT-737, a BCL-2 Inhibitor, in an NRAS/BCL2 Mouse Model of High Risk Myelodysplasia (HR-MDS) By Targeting Pathways Identified By Gene Expression Profiling

Blood (2014) 124 (21): 3249.

https://doi.org/10.1182/blood.V124.21.3249.3249

Published: 2014

Journal Articles

pVAX14 DNA, An Immunoadjuvant, Extends Life-Span As Add-On Treatment To Azacitidine (AZA) In A Mouse Model Of High Risk Myelodysplastic Syndrome (HR-MDS)

Gorombei Petra, Le Pogam Carole, MSc, Patricia Krief, PhD, Satyananda Patel, PhD, Guerenne Laura, West Robert, PhD, Pla Marika, PhD, Fenaux Pierre, Chomienne Christine, Rose Ann Padua, PhD

Blood (2013) 122 (21): 1514.

https://doi.org/10.1182/blood.V122.21.1514.1514

Published: 2013

Journal Articles

pVAX14 DNA, a Non-Specific DNA Vaccine, Improves Survival In An Acute Promyelocytic Leukemia (APL) Mouse Model Treated With All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO) and Targets Leukemia Initiating Cells (LICs)

Satyananda Patel, PhD, Laura Guerenne, Carole Le Pogam, Petra Gorombei, Patricia Krief, PhD, Marie-Helene Schlageter, Robert West, Vikram Mathews, MD, Marika Pla, PhD, Pierre Fenaux, MD, PhD, Christine Chomienne, MD, PhD, Rose Ann Padua, PhD

Blood (2013) 122 (21): 235.

https://doi.org/10.1182/blood.V122.21.235.235

Published: 2013

Journal Articles

BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells

Blood (2013) 122 (16): 2864–2876.

https://doi.org/10.1182/blood-2012-07-445635

Published: 2013

Includes: Supplemental data

Journal Articles

NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS)

Blood (2012) 120 (21): 3835.

https://doi.org/10.1182/blood.V120.21.3835.3835

Published: 2012

Journal Articles

ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2- Mediated Acute Myeloid Leukemia Progression with Increased Survival

Blood (2010) 116 (21): 3308.

https://doi.org/10.1182/blood.V116.21.3308.3308

Published: 2010

Journal Articles

DNA and All-Trans Retinoic Acid as Immunotherapy or Add-on Adjuvants to 5-Azacytidine In Myelodysplastic Syndromes

Carole Le Pogam, BSc, Patricia Krief, PhD, Stéphanie Beurlet, DMV, Murielle Reboul, Robert West, PhD, Marika Pla, PhD, Dominique Charron, MD, PhD, Pierre Fenaux, MD, PhD, Christine Chomienne, MD, PhD, Rose Ann Padua, PhD

Blood (2010) 116 (21): 2938.

https://doi.org/10.1182/blood.V116.21.2938.2938

Published: 2010

Journal Articles

DNA vaccination with all- trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4 + and CD8 + T-cell activation in an acute promyelocytic leukemia mouse model

Kouichi Furugaki, Katerina Pokorna, Carole Le Pogam, Masayuki Aoki, Murielle Reboul, Véronique Bajzik, Patricia Krief, Anne Janin, Marie-Elena Noguera, Robert West, Dominique Charron, Christine Chomienne, Marika Pla, Hélène Moins-Teisserenc, Rose Ann Padua

Blood (2010) 115 (3): 653–656.

https://doi.org/10.1182/blood-2007-08-109009

Published: 2010

Includes: Supplemental data

Journal Articles

DNA Vaccination and All-Trans Retinoic Acid Treatment-Induced Long Term Survival Requires CD4+ and CD8+ T-Cell Activation in An APL Mouse Model.

Rose Ann Padua, PhD, Kouichi Furugaki, MD, PhD, Helene Moins-Teisserenc, MD, PhD, Katerina Pokorna, Carole Le Pogam, Murielle Reboul, Masayuki Aoki, PhD, Veronique Bajzik, Patricia Krief, PhD, Anne Janin, MD, PhD, Maria-Elena Noguera, MD, Robert West, PhD, Marie-Helene Schlageter, PhD, Dominique Charron, MD, PhD, Marika Pla, PhD, Christine Chomienne, MD, PhD

Blood (2008) 112 (11): 962.

https://doi.org/10.1182/blood.V112.11.962.962

Published: 2008

Journal Articles

Implication of a New Molecule IK in CD34 + Hematopoietic Progenitor Cell Proliferation and Differentiation

Liang-Xian Cao, Marie-Caroline Le Bousse-Kerdilès, Denis Clay, Sergey Oshevski, Claude Jasmin, Patricia Krief

Blood (1997) 89 (10): 3615–3623.

https://doi.org/10.1182/blood.V89.10.3615

Published: 1997

NARROW

BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment

BCL-2 Inhibition with ABT-199 Shows Efficacy in AML Cell Lines with Synergistic Effects upon Addition of the MEK Inhibitor GDC-0973 and Prolongs Survival in an NAS/BCL-2-Mediated Mouse Model of AML Post-MDS

Efficacy of ABT-737, a BCL-2 Inhibitor, in an NRAS/BCL2 Mouse Model of High Risk Myelodysplasia (HR-MDS) By Targeting Pathways Identified By Gene Expression Profiling

pVAX14 DNA, An Immunoadjuvant, Extends Life-Span As Add-On Treatment To Azacitidine (AZA) In A Mouse Model Of High Risk Myelodysplastic Syndrome (HR-MDS)

pVAX14 DNA, a Non-Specific DNA Vaccine, Improves Survival In An Acute Promyelocytic Leukemia (APL) Mouse Model Treated With All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO) and Targets Leukemia Initiating Cells (LICs)

BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells

NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS)

ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2- Mediated Acute Myeloid Leukemia Progression with Increased Survival

DNA and All-Trans Retinoic Acid as Immunotherapy or Add-on Adjuvants to 5-Azacytidine In Myelodysplastic Syndromes

DNA vaccination with all- trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4 + and CD8 + T-cell activation in an acute promyelocytic leukemia mouse model

DNA Vaccination and All-Trans Retinoic Acid Treatment-Induced Long Term Survival Requires CD4+ and CD8+ T-Cell Activation in An APL Mouse Model.

Implication of a New Molecule IK in CD34 + Hematopoietic Progenitor Cell Proliferation and Differentiation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only